Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by nemo3on Jan 19, 2020 2:48pm

172 Views

Post# 30571244

RE:RE:RE:RE:RE:RE:TLT scratching the surface

Of course, this should read Ph 2 and NOT ph 3 but Stockhouse does not let you come back and edit one's mistakes. :)

nemo3 wrote: I love the thought of TLT being $200 but that is so far from the current time line that I too think more along the line of under a buck in the near future. We are still too early in this story. Not enough patients treated and showing a CR for the big investors to swoop in.

I have observed many times in clinical studies that the efficacy rate in a clinical study usually decreases as the studies advance. For instance, maybe Ph1 shows the treatment worked for 89% and phase 2 showed 62% and by the time the results are in for Ph3, it is down to 25%, This is not to say that TLT won't show high rates even in Ph3 but we don't know until we actually see the results of all the patients in Ph3 and that likely won't be till mid to late 2021. The fact that we have only 2 patients so far beyond the year mark with a CR means that we need more patients treated showing a CR at 1 year to blow this thing out of the water.

Now of course if 50 were done by early 2021 and results showed 100% CR or close to it, then this drug would be fast tracked. And what would that mean to the share price? Impossible to tell. Would it be $5? $15? $200.... I have no idea at all what the value will be.

Definitely need more patience on this one. Just hope the FDA situation is resolved ASAP so American urologists can start treatment for Ph 3. It seems to be a hurry up and wait scenario.

I will continue to hold my shares to see how the story unfolds. For NMBIC patients, I truly hope that this will be the treatment that will put them into remission forever. And for investors, I hope the share price rewards you handsomely.